Subscribe
shutterstock_249136888_niyazz
niyazz / Shutterstock.com
17 April 2019Big Pharma

Canadian generics plan could deter big pharma: report

Plans by Canada’s government to improve access to generic drugs could deter pharmaceutical companies from releasing brand medicine in the country, according to an internal government report.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Pharma industry challenges Canada’s drug pricing plan
9 September 2019   Innovative Medicines Canada, an association that represents drugmakers in Canada, has challenged the overhaul of Canada’s drug-pricing regime.


Editor's picks

‘We created law’: G1/24 and the creation of the ‘diamond standard’
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025

Editor's picks

Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

More on this story

Americas
Pharma industry challenges Canada’s drug pricing plan
9 September 2019   Innovative Medicines Canada, an association that represents drugmakers in Canada, has challenged the overhaul of Canada’s drug-pricing regime.

More on this story

Americas
Pharma industry challenges Canada’s drug pricing plan
9 September 2019   Innovative Medicines Canada, an association that represents drugmakers in Canada, has challenged the overhaul of Canada’s drug-pricing regime.

More features

‘We created law’: G1/24 and the creation of the ‘diamond standard’
BMS unit loses cell therapy patent at European Patent Office
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
Lord Justice Birss to become chancellor of the High Court
Bankruptcy judge approves $305m sale of genetics testing company
Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?